Among these innovative therapeutics to treat inflammatory components of atherosclerosis, the effects of lipid-lowering drugs on inflammatory biomarkers such as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors have been shown to substantially reduce LDL particles and cardiovascular event rates; however, their long-term safety and effects on cardiovascular risk are currently being investigated [205]. This evidence concerns the gene PCSK9 and atherosclerosis.